RGEN (Repligen) Other Current Liabilities: $31.5 Mil (As of Mar. 2026)


RGEN Repligen Corp RGEN
84 GF Score
Price $141.45
GF Value $176.53
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Repligen Other Current Liabilities?

Repligen RGEN -0.66% 84 Other Current Liabilities is $31.5 Mil as of Mar. 2026. GuruFocus rates RGEN with a GF Score™ of 84/100 and a GF Value™ of $176.53 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Repligen's other current liabilities for the quarter that ended in Mar. 2026 was $31.5 Mil.

Repligen's quarterly other current liabilities increased from Sep. 2025 ($41.1 Mil) to Dec. 2025 ($45.2 Mil) but then declined from Dec. 2025 ($45.2 Mil) to Mar. 2026 ($31.5 Mil).

Repligen's annual other current liabilities increased from Dec. 2023 ($29.6 Mil) to Dec. 2024 ($49.3 Mil) but then declined from Dec. 2024 ($49.3 Mil) to Dec. 2025 ($45.2 Mil).

Repligen Other Current Liabilities Related Terms

Repligen Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Repligen's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Repligen Other Current Liabilities Chart

Repligen Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 42.15 47.47 29.64 49.29 45.19

Repligen Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 65.57 40.88 41.15 45.19 31.50
RGEN
84GF Score
Repligen Corp RGEN
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Repligen Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of $31.5 Mil mean?
Repligen (RGEN) has a Other Current Liabilities of $31.5 Mil as of Mar. 2026. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Repligen.
Is Repligen's Other Current Liabilities too high?
Repligen's current Other Current Liabilities is $31.5 Mil. Overall, Repligen has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Repligen's Other Current Liabilities compare to ATR and AVTR?
Repligen's Other Current Liabilities of $31.5 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Medical Devices & Instruments company?
A good Other Current Liabilities depends on the Medical Devices & Instruments industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Repligen. Repligen's current Other Current Liabilities is $31.5 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Repligen stock overvalued right now?
Based on GuruFocus' analysis, Repligen (RGEN) is currently considered Modestly Undervalued. The stock's GF Value™ is $176.53, compared to a current price of $141.45 — trading 19.9% below its estimated fair value. The current Other Current Liabilities is $31.5 Mil. Repligen's overall GF Score™ is 84/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Repligen (RGEN), the current Other Current Liabilities is $31.5 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Repligen (RGEN) Overvalued in 2026?

Based on GuruFocus' analysis, Repligen stock appears to be undervalued. The current stock price of $141.45 is trading 19.9% below its estimated GF Value™ of $176.53. GuruFocus considers Repligen to be Modestly Undervalued.

Key valuation signals for RGEN:

  • Other Current Liabilities: $31.5 Mil
  • GF Value™: $176.53 vs. price of $141.45 (19.9% below fair value)
  • GF Score™: 84/100 with 5 warning signs

No single metric tells the full story. See the RGEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Repligen Business Description

Other Exchanges RGN:Germany
Address 41 Seyon Street, Building 1, Suite 100, Waltham, MA, USA, 02453
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category (about 55% of total revenue), while chromatography, proteins, and process analytics are 21%, 11%, and 13%, respectively. Customers in North America, Europe, and Asia Pacific contribute about 44%, 37%, and 19% of revenue, respectively.
84GF Score

Get the complete analysis for RGEN

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$141.45
Price
$176.53
GF Value